Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELVIs Study: Elvitegravir concentrations in seminal plasma in HIV-1 infected patients
2013-005116-10Phase 4Completed
- Sponsor
- Dr. Daniel Podzamczer Palter (Unidad de VIH. Servicio de Enfermedades Infecciosas. Hospital de Bellvitge).
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Dr. Daniel Podzamczer Palter (Unidad de VIH. Servicio de Enfermedades Infecciosas. Hospital de Bellvitge). Primary endpoint: Elvitegravir concentrations in seminal plasma at 4 weeks. Started Feb 2014; status: completed.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-005116-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005116-10.